Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov 1;140(11):2776-2796.
doi: 10.1093/brain/awx154.

Cell-based therapeutic strategies for multiple sclerosis

Neil J Scolding  1 , Marcelo Pasquini  2 , Stephen C Reingold  3 , Jeffrey A Cohen  4 ; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis
Collaborators, Affiliations
Review

Cell-based therapeutic strategies for multiple sclerosis

Neil J Scolding et al. Brain. .

Abstract

The availability of multiple disease-modifying medications with regulatory approval to treat multiple sclerosis illustrates the substantial progress made in therapy of the disease. However, all are only partially effective in preventing inflammatory tissue damage in the central nervous system and none directly promotes repair. Cell-based therapies, including immunoablation followed by autologous haematopoietic stem cell transplantation, mesenchymal and related stem cell transplantation, pharmacologic manipulation of endogenous stem cells to enhance their reparative capabilities, and transplantation of oligodendrocyte progenitor cells, have generated substantial interest as novel therapeutic strategies for immune modulation, neuroprotection, or repair of the damaged central nervous system in multiple sclerosis. Each approach has potential advantages but also safety concerns and unresolved questions. Moreover, clinical trials of cell-based therapies present several unique methodological and ethical issues. We summarize here the status of cell-based therapies to treat multiple sclerosis and make consensus recommendations for future research and clinical trials.

Keywords: clinical trials; medical ethics; multiple sclerosis and neuroinflammation; remyelination; stem cells.

PubMed Disclaimer

Comment in

References

    1. Abrahamsson SV, Angelini DF, Dubinsky AN, Morel E, Oh U, Jones JL, et al. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain 2013; 136: 2888–903. - PMC - PubMed
    1. Akiyama Y, Radtke C, Honmou O, Kocsis JD. Remyelination of the spinal cord following intravenous delivery of bone marrow cells. Glia 2002; 39: 229–36. - PMC - PubMed
    1. Arruda LC, Lorenzi JC, Sousa AP, Zanette DL, Palma PV, Panepucci RA, et al. Autologous hematopoietic SCT normalizes miR-16, -155, 142‐3p expression in multiple sclerosis patients. Bone Marrow Transplant 2015; 50: 380–9. - PubMed
    1. Atkins HL, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, et al. Immunoablation and autologous haematopoietic stem-cell transplanatation for agressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet 2016; 388: 576–85. - PubMed
    1. Autoimmune Disease Working Party. History of the Autoimmune Diseases Working Party, reason for its establishment and its context within the EBMT. Available from: https://www.ebmt.org/Contents/Research/TheWorkingParties/ADWP/Pages/Auto... (22 August 2016, date last accessed).

MeSH terms